The findings are consistent with a previous study of lung cancer [32], where the expression of ELMO3 was significantly upregulated in the tissues and serum from non-small cell lung cancer (NSCLC) patients, significantly associated with many clinicopathological characteristics and can be used as a potential diagnostic and prognostic marker. This evidence concerns the gene ELMO3 and non-small cell lung carcinoma.